Frankfurt - Delayed Quote EUR

Immutep Limited (YP1A.F)

Compare

1.9400

-0.0500

(-2.51%)

As of 8:06:45 AM GMT+1. Market Open.

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for YP1A.F

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immutep Limited (YP1A.F)

Comparisons

Indicators

Technicals

Corporate Events

-4.90%

2.65%

-20.49%

-8.49%

-5.83%

29.33%

-84.68%

Recent News: YP1A.F

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep announces results from Cohort B of TACTI-003 trial

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024